(Q37857329)

24 August 2017

1 reference

title

Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting (English)

1 reference

24 August 2017

1 reference

Richard Hargreaves

1

1 reference

24 August 2017

Juan Camilo Arjona Ferreira

2

1 reference

24 August 2017

David Hughes

3

1 reference

24 August 2017

Jos Brands

4

1 reference

24 August 2017

Jeff Hale

5

1 reference

24 August 2017

Britta Mattson

6

1 reference

24 August 2017

Sandy Mills

7

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Annals of the New York Academy of Sciences

24 August 2017

published in

1 reference

24 August 2017

volume

1222

1 reference

24 August 2017

page(s)

40-48

1 reference

An unidentified depressor substance in certain tissue extracts

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

The distribution of substance P and 5-hydroxytryptamine in the central nervous system of the dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Clinical biomarkers in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Efficient synthesis of NK(1) receptor antagonist aprepitant using a crystallization-induced diastereoselective transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Neurokinin-1 and novel serotonin antagonists for postoperative and postdischarge nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Central neurocircuitry associated with emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05961.X

10.1111/J.1749-6632.2011.05961.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference